Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: June 2014

20 - Management of intracranial hemorrhage: early expansion and second bleeds

from Section 4 - Critical Care of Intracranial Hemorrhage

References

[1] Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10 year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009;40:394–9.
[2] Broderick J, Brott T, Duldner JE, Tomsick T, Huster G. Volume of intracrerbral hemorrhage: A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993;24:987–93.
[3] Herbstein DJ, Schaumberg HH. Hypertensive intracerebral hematoma. An investigation of the initial hemorrhage and rebleeding using chronium cr 51-labeled erythrocytes. Arch Neurol. 1974;30:412–14.
[4] Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28(1):1–5.
[5] Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1–5.
[6] Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17.
[7] Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880–4.
[8] Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175–81.
[9] Leira R, Davalos A, Silva Y, et al. Early neurologic deterioration in intracerebral hemorrhage: Predictors and associated factors. Neurology. 2004;63:461–7.
[10] Steiner T, Bösel J. Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage. Stroke. 2010;40:3275–80.
[11] Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular blood is an important determinant of outcome in supratentorial intracerebral hemorrhage. Crit Care Med. 1999;27(3):617–21.
[12] Steiner T, Schneider D, Mayer S, et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006;59:767–74.
[13] Maas MB, Nemeth AJ, Rosenberg NF, et al. Delayed intraventricular hemorrhage is common and worsens outcomes in intracerebral hemorrhage. Neurology. 2013;80(14):1295–9.
[14] Kase CS, Mohr JP, Caplan LR, eds. Intracerebral hemorrhage. Stroke: Pathophysiology, Diagnosis, and Management. 4 ed: Philadelphia: Churchill Livingstone, 2004.
[15] Xi G. Intracerebral hemorrhage: Pathophysiology and therapy. Neurocritical Care. 2004;1:5–18.
[16] Kim-Han JS, Kopp SJ, Dugan LL, Diringer MN. Perihematomal mitochondrial dysfunction after intracerebral hemorrhage. Stroke. 2006;37:2457–62.
[17] Silva Y, Leira R, Tejada J, et al. Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke. 2005;36:86–91.
[18] Florczak-Rzepka M, Grond-Ginsbach C, Montaner J, Steiner T. Matrix metalloproteinases in human spontaneous intracerebral hemorrhage – an update. Cerebrovasc Dis. 2012;34:249–62.
[19] Alvarez-Sabin J, Delgado P, Abilleira S, et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage: Relationship to clinical and radiological outcome. Stroke. 2004;35:1316–22.
[20] Naidech AM, Jovanovic B, Liebling S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009;40:2398–401.
[21] Delgado P, Alvarez-Sabin J, Abilleira S, et al. Plasma d-dimer predicts poor outcome after acute intracerebral hemorrhage. Neurology. 2006;67:94–8.
[22] Sorimachi T, Fujii Y, Morita K, Tanaka R. Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control. J Neurosurg. 2007;106:250–4.
[23] Saloheimo P, Ahonen M, Juvela S, et al. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006;37:129–33.
[24] Broderick JP, Diringer MN, Hill MD, et al. Determinants of intracerebral hemorrhage growth: An exploratory analysis. Stroke. 2007;38:1072–5.
[25] Goldstein JN, Fazen LE, Snider R, et al. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology. 2007;68:889–94.
[26] Delgado Almandoz JE, Yoo AJ, Stone MJ, et al. Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: The spot sign score. Stroke. 2009;40:2994–3000.
[27] Li N, Wang Y, Wang W, et al. Contrast extravasation on computed tomography angiography predicts clinical outcome in primary intracerebral hemorrhage, a prospective study of 139 cases. Stroke. 2011;42:3441–6.
[28] Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): a prospective observational study. Lancet Neurol. 2012;11:307–14.
[29] Morgenstern LB, Frankowski RF, Shedden P, Pasteur W, Grotta JC. Surgical treatment for intracerebral hemorrhage (STICH): A single-center, randomized clinical trial. Neurology. 1998;51:1359–63.
[30] Morgenstern LB, Demchuk AM, Kim DH, Frankowski RF, Grotta JC. Rebleeding leads to poor outcome in ultra-early craniotomy for intracerebral hemorrhage. Neurology. 2001;56:1294–9.
[31] NINDS ICH Workshop Participants. Priorities for clinical research in intracerebral hemorrhage. Report from a National Institute of Neurologic Disorders and Stroke Workshop. Stroke. 2005;36:e23–e41.
[32] Mendelow AD, Gregson BA, Rowan EN, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet. 2013; May 29.
[33] Mendelow AD, Unterberg A. Surgical treatment of intracerebral haemorrhage. Curr Opin Crit Care. 2007;13:169–74.
[34] Auer LM, Deinsberger W, Niederkorn K, et al. Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: A randomized study. J Neurosurg. 1989;70:530–5.
[35] Cho DY, Chen CC, Lee WY, Lee HC, Ho LH. A new modified intracerebral hemorrhage score for treatment decisions in basal ganglia hemorrhage – a randomized trial. Crit Care Med. 2008;36:2151–6.
[36] Qureshi AI. Acute hypertensive response in patients with stroke: pathophysiology and management. Circulation. 2008;118:176–87.
[37] Morgenstern LB, Hemphill JC 3rd, Anderson C et al. Nursing at AHASCaCoC. Guidelines for the management of spontaneus intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Assiciation. Stroke. 2010;41:2108–29.
[38] Ohwaki K, Yano E, Nagashima H, et al. Blood pressure management in acute intracerebral hemorrhage: Relationship between elevated blood pressure and hematoma enlargement. Stroke. 2004;35:1364–7.
[39] Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (interact): A randomised pilot trial. Lancet Neurol. 2008;7:391–9.
[40] Qureshi AI, Tariq N, Divani AA et al., and the ATACH investigators. Antihypertensive treatment of acute cerebral hemorrhage (ATACH). Critical Care Medicine. 2010;38:637–48.
[41] Qureshi AI, Palesch YY. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care. 2011;15(3):559–76.
[42] Koch S, Romano JG, Forteza AM, Otero CM, Rabinstein AA. Rapid blood pressure reduction in acute intracerebral hemorrhage: Feasibility and safety. Neurocrit Care. 2008;8:316–21.
[43] Diedler J, Sykora M, Rupp A, et al. Impaired cerebral vasomotor activity in spontaneous intracerebral hemorrhage. Stroke. 2009;40:815–19.
[44] Morgenstern LB, Hemphill JC, 3rd, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108–29.
[45] Broderick JP, Connolly ES, Feldman E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults. 2007 update. A guideline from the American Heart Association, American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007;38:e391–413.
[46] Steiner T, Kaste M, Forsting M, et al. Recommendations for the management of intracranial haemorrhage – part 1: Spontaneous intracerebral haemorrhage. The European Stroke Initiative writing committee and the writing committee for the Eusi Executive Committee. Cerebrovasc Dis. 2006;22:294–316.
[47] Gould B, McCourt R, Asdaghi N, et al. Autoregulation of cerebral blood flow is preserved in primary intracerebral hemorrhage. Stroke. 2013;44:1726–8.
[48] Greer DM, Funk SE, Reaven NL, Ouzounelli M, Uman GC. Impact of fever on outcome in patients with stroke and neurologic injury: a comprehensive meta-analysis. Stroke. 2008;39:3029–35.
[49] Reith J, Jorgensen HS, Pedersen PM, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996;347:422–5.
[50] Balami JS, Buchan AM. Complications of intracerebral haemorrhage. Lancet Neurol. 2012;11:101–18.
[51] den Hertog HM, van der Worp HB, van Gemert HM, et al. The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial. Lancet Neurol. 2009;8:434–40.
[52] Paracetamol (Acetaminophen) in Stroke 2 (PAIS 2): A randomized clinical trial to investigate the effect of high-dose paracetamol in patients with acute stroke and a body temperature of 37.0°C or above. http://wwwtrialregisternl/trialreg/admin/rctviewasp?TC=2365, 2612012, 2010.
[53] Mayer S, Brun N, Broderick J, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–85.
[54] Mayer S, Brun N, Broderick J, et al. Efficacy and safety of recombinant activated factor vii for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–37.
[55] Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:116–21.
[56] Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–64.
[57] Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26:1471–7.
[58] Rosand J, Hylek EM, O’Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study. Neurology. 2000;55:947–51.
[59] Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion. Mayo Clin Proc. 2007;82:82–92.
[60] Huttner HB, Schellinger PD, Hartmann M, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy. Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465–70.
[61] Steiner T, Freiberger A, Griebe M, et al. International normalised ratio normalisation in patients with coumarin-related intracranial haemorrhages – the INCH trial: a randomised controlled multicentre trial to compare safety and preliminary efficacy of fresh frozen plasma and prothrombin complex – study design and protocol. Int J Stroke. 2011;6(3):271–7.
[62] Boeer A, Voth E, Henze T, Prange HW. Early heparin therapy in patients with spontaneous intracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 1991;54:466–7.
[63] Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34:1710–11.
[64] Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke. 2004;35:1415–20.
[65] Majeed A, Kim Y, Roberts R, Holmström M, Schulman S. Optimal timing of resumption of wafarin after intracranial hemorrhage. Stroke. 2010;41:2860–6.
[66] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
[67] Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–83.
[68] Steiner T, Bohm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with new direct oral anticoagulants (doac) apixaban, dabigatran, and rivaroxaban. Clinical Res Cardiol. 2013;102:399–412.
[69] Zhou W, Schwarting S, Illanes S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594–9.
[70] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
[71] Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011: 124.
[72] Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137–43.
[73] van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27.
[74] van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.
[75] Piriyawat P, Morgenstern LB, Yawn D, Hall CE, Grotta JC. Treatment of acute intracerebral hemorrhage with e-aminocaproic acid – a pilot study. Neurocritical Care. 2004;1:47–51.
[76] Vujkovac B, Sabovic M. Treatment of subdural and intracerebral haematomas in a haemodialysis patient with tranexamic acid. Nephrol Dial Transplant. 2000;15:107–9.
[77] Carhuapoma JR, Barrett RJ, Keyl PM, Hanley DF, Johnson RR. Stereotactic aspiration-thrombolysis of intracerebral hemorrhage and its impact on perihematoma brain edema. Neurocrit Care. 2008;8:322–9.
[78] Morgan T, Zuccarello M, Narayan R, et al. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl. 2008;105:147–51.
[79] The Medicines Company. Clevidipine in the treatment of patients with acute hypertension and intracerebral hemorrhage (accelerate). http://clinicaltrialsgov/show/NCT00666328; Acess date: 16.3.2009.
[80] Lyden PD, Shuaib A, Lees KR, et al. Safety and tolerability of nxy-059 for acute intracerebral hemorrhage: The chant trial. Stroke. 2007;38:2262–9.
[81] Wang J, Tsirka SE. Tuftsin fragment 1–3 is beneficial when delivered after the induction of intracerebral hemorrhage. Stroke. 2005;36:613–18.
[82] Lee ST, Chu K, Jung KH, et al. Memantine reduces hematoma expansion in experimental intracerebral hemorrhage, resulting in functional improvement. J Cereb Blood Flow Metab. 2006;26:536–44.
[83] Lee ST, Chu K, Sinn DI, et al. Erythropoietin reduces perihematomal inflammation and cell death with enos and stat3 activations in experimental intracerebral hemorrhage. J Neurochem. 2006;96:1728–39.
[84] Sinn DI, Kim SJ, Chu K, et al. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis. 2007;26:464–72.